ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

China

Peking University Cancer Hospital, Beijing

Hunan Cancer Hospital, Changsha

Xiangya Hospital Central South University, Changsha

West China hospital, sichuan university, Chengdu

The First Affiliate Hospital of GUANGZHOU Medical University, Guangzhou

Yunnan Cancer Hospital, Kunming

Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing

Guangxi Medical University Cancer Hospital, Nanning

Fudan University Cancer Hospital, Shanghai

Liaoning Tumor Hospital, Shengyang

Shengjing Hospital of China Medical University, Shengyang

The First Hospital of China Medical University, Shengyang

Hubei Cancer Hospital, Wuhan

Tongji Hospital, Wuhan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou